Egetis Therapeutics: Continued progress in Q4 - Redeye

Redeye updates its view of Egetis following the Q4 report and recent events in the company. The company has made some good progress and we see 2024 as a pivotal year for the company in its transformation to a soon commercial company.

Länk till analysen i sin helhet: https://www.redeye.se/research/985298/egetis-therapeutics-continued-progress?utm_source=finwire&utm_medium=RSS